Anatara Lifesciences Provided the Summary of GaRP Dietary Supplement

  • Jan 22, 2020 AEDT
  • Team Kalkine

Anatara Lifesciences Ltd (ASX: ANR) has provided the summary of the preclinical studies for its Gastrointestinal ReProgramming (GaRP) dietary supplement as it targets commencement of a human clinical trial in 2Q 2020.

Successful preclinical program has provided strong scientific proof that GaRP dietary supplement of Anatara may be the breakthrough product that is urgently required by the patients who suffers from chronic bowel conditions.

In summary, GaRP:

  • Addressed the dysbiosis of the microbiome
  • Reduced gut inflammation
  • Promoted mucosal healing

GaRP is capable of providing:

  • An adjuvant effect in lessening inflammation with the co-administration of disease-modifying medications.
  • Dose decrease of disease-modifying medications known to have harmful side-effect.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK